{"id":2141,"date":"2007-01-01T12:04:00","date_gmt":"2007-01-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/etoricoxib-oder-diclofenac-das-medal-programm-ein-reanimationsversuch"},"modified":"2007-01-01T12:04:00","modified_gmt":"2007-01-01T11:04:00","slug":"etoricoxib-oder-diclofenac-das-medal-programm-ein-reanimationsversuch","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/etoricoxib-oder-diclofenac-das-medal-programm-ein-reanimationsversuch","title":{"rendered":"Etoricoxib oder Diclofenac? Das MEDAL-Programm: Ein Reanimationsversuch"},"content":{"rendered":"<p>MEDAL steht f\u00fcr Multinational Etoricoxib and Diclofenac Arthritis Long-term programme. Die Ergebnisse sind im November 2006 im Lancet ver\u00f6ffentlicht worden (1). Es sollte nachgewiesen werden, dass Etoricoxib nicht h\u00e4ufiger kardiovaskul\u00e4re Nebenwirkungen verursacht als Diclofenac. Wir erinnern uns: Im September 2004 war Rofecoxib (Vioxx\u00ae, Hersteller: Merck) und im April 2005 Valdecoxib (Bextra\u00ae, Hersteller: Pfizer) aus dem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MEDAL steht f\u00fcr Multinational Etoricoxib and Diclofenac Arthritis Long-term programme. Die Ergebnisse sind im November 2006 im Lancet ver\u00f6ffentlicht worden (1). Es sollte nachgewiesen werden, dass Etoricoxib nicht h\u00e4ufiger kardiovaskul\u00e4re Nebenwirkungen verursacht als Diclofenac. Wir erinnern uns: Im September 2004 war Rofecoxib (Vioxx\u00ae, Hersteller: Merck) und im April 2005 Valdecoxib (Bextra\u00ae, Hersteller: Pfizer) aus dem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1355,1360,611,4331,1368,3912,1350],"class_list":["post-2141","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cox-2-hemmer","tag-coxibe","tag-diclofenac","tag-edge-studien","tag-etoricoxib","tag-medal-programm","tag-zyklooxygenase-2-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2141"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2141\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}